Literature DB >> 15632953

Single-dose pharmacokinetics of a novel oral platinum cytostatic drug ([OC-6-43]-bis[acetato][1-adamantylamine]amminedichloroplatinum [IV]) in pigs.

J Cermanova1, J Chladek, P Soval, A Kroutil, M Semerad, Z Berankova, P Siroky, I Surova.   

Abstract

The pharmacokinetics of total platinum (Pt) were investigated after a single oral dose of (OC-6-43-bis(acetato)(1-adamantylamine)amminedichloroplatinum (IV) (LA-12). A dose of 3 mg/kg (n = 3) and 30 mg/kg (n = 3) was given to two parallel groups of pigs (n = three each). Pt was measured in the blood, urine and feces by atomic absorption spectrometry. Blood was sampled at specified times until 240 h, urine was obtained through a catheter at 1-h intervals until 6 h, and feces were collected until 240 h after administration. LA-12 was rapidly absorbed, as indicated by a T(max) of total Pt within 0.5-1.5 h after administration. The mean (SEM) values for maximum plasma concentration (0.060 +/- 0.025 and 0.39 +/- 0.08 mg/l) and the area under the plasma concentration vs. time curve (12.6 +/- 5.6 and 36.3 +/- 2.0 mg.h/l) increased less than proportionally to the increase in the dose. The mean (SEM) Pt urinary excretion determined over a 6-h postdose period achieved only 1.9% and 0.8% of the administered doses, respectively. Within 2 h after dosing, the renal clearance of total Pt was approximately 2-fold higher than that of creatinine (CL(cr)). Thereafter, it steadily dropped and in the last collection interval (5-6 h postdose) its value was 50% less than CL(cr). Platinum recoveries in feces over 10 days after dosing reached 0.4% and 2.6% of the administered dose, respectively. This finding indicates that the extent of absorption of both doses was high. There were no changes in results of hematology and clinical biochemistry tests. Copyright 2004 Prous Science. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15632953     DOI: 10.1358/mf.2004.26.9.872565

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  4 in total

1.  The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin.

Authors:  Veronika Kvardova; Roman Hrstka; Dawid Walerych; Petr Muller; Eva Matoulkova; Veronika Hruskova; Dagmar Stelclova; Petr Sova; Borivoj Vojtesek
Journal:  Mol Cancer       Date:  2010-06-15       Impact factor: 27.401

2.  Different cell cycle modulation following treatment of human ovarian carcinoma cells with a new platinum(IV) complex vs cisplatin.

Authors:  Viktor Horváth; Karel Soucek; Lenka Svihálková-Sindlerová; Jan Vondrácek; Olga Blanárová; Jirina Hofmanová; Petr Sova; Alois Kozubík
Journal:  Invest New Drugs       Date:  2007-05-23       Impact factor: 3.850

3.  The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo.

Authors:  Pavel Bouchal; Jiri Jarkovsky; Kristyna Hrazdilova; Monika Dvorakova; Iva Struharova; Lenka Hernychova; Jiri Damborsky; Petr Sova; Borivoj Vojtesek
Journal:  Proteome Sci       Date:  2011-10-31       Impact factor: 2.480

4.  Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism.

Authors:  Alois Kozubík; Alena Vaculová; Karel Soucek; Jan Vondrácek; Jaroslav Turánek; Jirina Hofmanová
Journal:  Met Based Drugs       Date:  2008
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.